Bilirubin

Bilirubin

SCHEMBL2942018

C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O.[PbH2]

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.98
MEN1 O00255 1/20 0.98
ALDH1A1 P00352 1/20 0.98
LMNA P02545 1/20 0.98
MAPT P10636 1/20 0.98
CASP1 P29466 1/20 0.98
CASP7 P55210 1/20 0.98
KMT2A Q03164 1/20 0.98
HSD17B10 Q99714 1/20 0.98
SLCO1B3 Q9NPD5 1/20 0.98
TDP1 Q9NUW8 1/20 0.98
SLCO1B1 Q9Y6L6 1/20 0.98
P2RX7 Q99572 1/20 0.90
ABCC1 P33527 2/20 0.70
ABCC2 Q92887 2/20 0.70
KDR P35968 13/20 0.38
FGFR1 P11362 12/20 0.38
PDGFRB P09619 11/20 0.38
FLT3 P36888 3/20 0.38
AURKB Q96GD4 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bilirubin SCHEMBL3361472 0.99 KDM4E (1.00) KDM4EMEN1ALDH1A1LMNAMAPT
Bilirubin SCHEMBL10565617 0.99 KDM4E (1.00) KDM4EMEN1ALDH1A1LMNAMAPT
Bilirubin SCHEMBL5086205 0.99 KDM4E (1.00) KDM4EMEN1ALDH1A1LMNAMAPT
Bilirubin SCHEMBL19065 0.99 KDM4E (1.00) KDM4EMEN1ALDH1A1LMNAMAPT
Bilirubin SCHEMBL32671479 0.99 KDM4E (1.00) KDM4EMEN1ALDH1A1LMNAMAPT
Bilirubin SCHEMBL23529823 0.98 KDM4E (0.98) KDM4EMEN1ALDH1A1LMNAMAPT
Bilirubin SCHEMBL5493673 0.98 KDM4E (0.98) KDM4EMEN1ALDH1A1LMNAMAPT
Bilirubin SCHEMBL11412908 0.98 KDM4E (0.98) KDM4EMEN1ALDH1A1LMNAMAPT
Bilirubin SCHEMBL6735045 0.98 KDM4E (0.98) KDM4EMEN1ALDH1A1LMNAMAPT
Bilirubin SCHEMBL9116171 0.98 KDM4E (0.98) KDM4EMEN1ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3010556-B1 MATRIX AND IMPLANT FOR TISSUE ENGINEERING BAER HANS U (CH) 2019-01-30 EP disclosed
EP-2815773-B1 Matrix and implant for tissue engineering BAER HANS U (CH) 2017-08-30 EP disclosed
US-20160130558-A1 MATRIX AND IMPLANT FOR TISSUE ENGINEERING BAER HANS U (CH) 2016-05-12 US disclosed
EP-3010556-A1 MATRIX AND IMPLANT FOR TISSUE ENGINEERING Baer, Hans U. (CH) 2016-04-27 EP disclosed
WO-2014202199-A1 MATRIX AND IMPLANT FOR TISSUE ENGINEERING BAER HANS U (CH) 2014-12-24 WO disclosed
EP-2815773-A1 Matrix and implant for tissue engineering Baer, Hans U. (CH) 2014-12-24 EP disclosed
US-8344019-B2 Methods for the production of biliverdin THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2013-01-01 US disclosed
US-8309115-B2 Matrix, cell implantation and method for their production and use HUMANAUTOCELL GMBH (DE) 2012-11-13 US disclosed
US-20120142751-A1 METHODS FOR THE PRODUCTION OF BILIVERDIN THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF (US) 2012-06-07 US disclosed
US-20100028405-A1 MATRIX, CELL IMPLANTATION AND METHOD FOR THEIR PRODUCTION AND USE HUMANAUTOCELL GMBH (DE) 2010-02-04 US disclosed
US-7618646-B2 Matrix, cell implant and method for their production and use HUMANAUTOCELL GMBH (DE) 2009-11-17 US disclosed
US-20090203762-A1 METHODS FOR THE PRODUCTION OF BILIVERDIN THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES 2009-08-13 US disclosed
US-7504243-B2 Methods for the production of biliverdin THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2009-03-17 US disclosed
US-20070166343-A1 Matrix, cell implantation and method for their production and use HUMANAUTOCELL GMBH (DE) 2007-07-19 US disclosed
US-20050209305-A1 Methods for the production of biliverdin PENDRAK MICHAEL L 2005-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070166343-A1 Matrix, cell implantation and method for their production and use IAPP, MMP1, CD68 KDM4E 3891/4885MEN1 646/4885ALDH1A1 2195/4885
US-20100028405-A1 MATRIX, CELL IMPLANTATION AND METHOD FOR THEIR PRODUCTION AND USE IAPP, MMP1, CD68 KDM4E 3891/4885MEN1 646/4885ALDH1A1 2195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.